Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

PHOTON and PULSAR data presentations demonstrate aflibercept 8 mg led to sustained improvements in vision and anatomic measures of retinal fluid across the 48-week treatment period in both 12- and 16-week dosing regimens TARRYTOWN, N.Y., Sept. 30, 2022 /PRNewswire/ — Regeneron…

Click here to view original post